Based on its latest report, data and analytics company — GlobalData — has revealed that North Americans are the least informed about the General Data Protection Regulation (GDPR).
North America
The ‘General Data Protection Regulation (GDPR) in the Healthcare Industry Implications for Pharma — H1 2018’ report highlighted that only 54% of North Americans felt informed about the new EU regulation compared with 84% in Europe and Asia-Pacific and 67% of those in other global regions.
“These results suggest that those in the US pharmaceuticals industry may be less prepared than in other regions, when it comes to adopting the new business practices needed to meet requirements set out by the GDPR,” stated Thomas Moore, senior pharma analyst at GlobalData. “This observation could be due to GDPR having arguably less of a direct impact on companies operating in North America than those in other global regions, which are often more dependent on EU business operations.”
This report was based on a broader survey of participants from across industry sectors who were asked about changes to their business practice due to GDPR in addition to their sentiment towards the legislation. Focusing on the responses from those in the pharmaceutical industry, with the key objectives being to benchmark the factors which impact the healthcare sector, determine challenges with GDPR compliance, and track changes to corporate strategy.
“GDPR was a piece of legislation brought into effect by the EU on 25 May 2018, which aims to provide EU citizens with greater rights and control regarding the processing and distribution of their personal data,” continued Moore. “Due to the complexity of the regulations, it is essential that businesses stay highly informed should they wish to continue operating within EU member states. GlobalData’s report aims to provide insight on how companies in the healthcare industry have responded to GDPR globally.”